Bellevue Asset Management, LLC Argenx Se Transaction History

Bellevue Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 12, 2021	SELL	$268.3 - $380.31 $2,414 - $3,422	-9 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$248.13 - $308.36 $992 - $1,233	-4 Reduced 30.77%	9 $3,000
Q3 2020 Nov 12, 2020	SELL	$215.51 - $272.51 $862 - $1,090	-4 Reduced 23.53%	13 $3,000
Q1 2020 May 13, 2020	BUY	$108.83 - $165.23 $870 - $1,321	8 Added 88.89%	17 $2,000
Q4 2019 Feb 13, 2020	BUY	$106.59 - $164.21 $959 - $1,477	9 New	9 $1,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Bellevue Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bellevue Asset Management, LLC with notifications on news.